This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Thoracic Guidelines

May 3, 2014
This systematic review and meta-analysis of individual patient data from 15 RCTs (2385 pts) assessed the utility of preoperative chemotherapy in patients with primarily stages Ib-IIIa NSCLC.  Chemotherapy resulted in a 13% reduction in death (HR 0.87, p=0.007), and a 5% survival improvement at 5 years.
May 1, 2014
A panel for the Centers for Medicare and Medicaid determined that annual low-dose CT screening for lung cancer carries too high a risk related to the potential benefits.  They expressed concern about high false-positive rates, quality assurance, and gaps in evidence as to how the CT results would be used.  Despite the fact that many professional grou
March 7, 2014
LVI is thought to be an adverse prognostic indicator of survival in patients with NSCLC.  This review quantified the relationship of LVI and survival.  The unadjusted effect of LVI for recurrence-free survival was HR=3.63 and for overall survival was HR=2.38.  After adjustment for covarates, these HRs were 2.52 and 1.81, both highly significant.